Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer ; volume:10 ; number:1 ; day:13 ; month:4 ; year:2010 ; pages:1-9 ; date:12.2010
BMC cancer ; 10, Heft 1 (13.4.2010), 1-9, 12.2010
- Urheber
-
Sánchez-Muñoz, Alfonso
- Beteiligte Personen und Organisationen
-
Gallego, Elena
de Luque, Vanessa
Pérez-Rivas, Luís G.
Vicioso, Luís
Ribelles, Nuria
Lozano, José
Alba, Emilio
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-10-136
- URN
-
urn:nbn:de:1111-2016030354665
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sánchez-Muñoz, Alfonso
- Gallego, Elena
- de Luque, Vanessa
- Pérez-Rivas, Luís G.
- Vicioso, Luís
- Ribelles, Nuria
- Lozano, José
- Alba, Emilio
- SpringerLink (Online service)
Ähnliche Objekte (12)
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Oncogenic potential of rare RRAS2 mutations
The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Oncogenic potential of rare RRAS2 mutations
The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Oncogenic potential of rare RRAS2 mutations